Adam Weiner, Urologic Surgeon at Cedars-Sinai, shared a post on X about a paper by Amar Kishan et.al published in JAMA Oncology :
“SGLT2 inhibitors and ADT failure for patients with Prostate Cancer
JAMA Oncology study (n=14,223) using target-trial emulation SGLT2 inhibitors
- Decreased ADT failure by 37% (HR 0.63)
- Decreased next-gen hormonal therapy failure by 56% (HR 0.44)
- No major difference dapagliflozin vs empagliflozin
- Effect seems independent of glucose control
- Observational → strong signal for repurposing SGLT2 inhibitors in PCa
Prospective trials needed!”
Title: Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Prostate Cancer Undergoing Hormone Therapy
Authors: Ruofan Shi, Yongle Zhan, Ruochen Ma
You can read the full article in JAMA Oncology.
More posts featuring Adam Weiner.